Key Points - Guizhou Moutai elected Chen Hua as the chairman of the fourth board of directors and plans to repurchase shares between RMB 1.5 billion and RMB 3 billion [1] - Tianfeng Securities is under investigation by the China Securities Regulatory Commission for suspected violations of information disclosure and illegal financing [1] Share Buybacks - Demai Technology raised the upper limit for share repurchase to RMB 45 per share [5] - Jianbang Technology plans to repurchase shares worth between RMB 15 million and RMB 30 million [5] - Huayuan Holdings intends to repurchase shares worth between RMB 30 million and RMB 60 million [5] Major Investments - Jinling Pharmaceutical plans to invest RMB 893 million in hospital expansion projects [7] - Dongfang Mingzhu intends to invest approximately RMB 500 million to establish a partnership and acquire part of the equity of New H3C [7] - Chang'an Automobile aims to establish a robotics company to develop innovative products and solutions [7] Mergers and Acquisitions - Kaizhong Co. plans to acquire 60% of Anhui Tuosheng's equity, with stock resuming trading on December 1 [7] - Youa Co. has resumed the review process for issuing shares and cash to purchase assets [7] - Jiasheng Technology intends to acquire controlling interest in Shudun Information Technology Co., with stock continuing to be suspended [7] Financing Activities - Shenzhen Energy plans to apply for a public bond issuance with a total scale not exceeding RMB 20 billion [7] - Huakong Saige has terminated its specific object stock issuance [7]

Group 1 - Jianbang Co., Ltd. plans to repurchase shares using self-owned funds between 15 million and 30 million yuan, with a maximum price of 38 yuan per share [1] - Yatong Precision Engineering's investment in a private equity fund has been terminated due to failure to complete the agreed investment, leading to the fund's dissolution [1] - China Storage Co., Ltd. intends to invest 1.129 billion yuan in the Sanjiang Port project, with its wholly-owned subsidiary contributing 500 million yuan to establish a project company [2] Group 2 - Guangxin Co., Ltd. plans to inject assets worth 4.383 billion yuan into its wholly-owned subsidiary, increasing its registered capital from 10 million to 20 million yuan [3] - Jiangxin Home plans to use up to 3 billion yuan of idle self-owned funds for cash management in low-risk financial products [4] - Huangshan Tourism intends to lease part of the Huangshan scenic area for 1.27 billion yuan over a 10-year period [5] Group 3 - Jilin Expressway's general manager has resigned due to work adjustments [6] - Guoyao Modern's subsidiary has received a drug registration certificate for hydromorphone hydrochloride injection, suitable for pain management [8] - Hangya Technology plans to invest up to 70 million USD to establish subsidiaries in Singapore and Malaysia [10] Group 4 - ST Sailong's subsidiary has received approval for the listing of two chemical raw materials [11] - Shanghai Pharmaceuticals' tramadol hydrochloride injection has passed the consistency evaluation for generic drugs [12] - Yubang Electric has obtained a laboratory accreditation certificate from CNAS, indicating its testing capabilities [14] Group 5 - ST Lifang's stock will be subject to delisting risk warning starting December 1 due to administrative penalties [15] - Zhejiang Longsheng is investing 200 million yuan in a private equity partnership focused on high-potential enterprises [15] - Huayang Co., Ltd.'s subsidiary has obtained safety production permits, allowing it to commence production [16] Group 6 - Xujie Electric has won a bid for a State Grid project worth 1.518 billion yuan [17] - Pinggao Electric and its subsidiaries have collectively won a State Grid project worth approximately 773 million yuan [17] - ST Lanhua's subsidiary has entered the trial production phase for a juice beverage project with a total investment of up to 65 million yuan [18] Group 7 - Huakong Saige has terminated its stock issuance plan due to various considerations [19] - Yatong Co., Ltd. plans to invest 36 million yuan to establish a joint venture in renewable energy [20] - Warner Pharmaceuticals has received a drug registration certificate for a new inhalation solution for COPD patients [21] Group 8 - Demais has raised the upper limit for its share repurchase price to 45 yuan per share [22] - China West Electric's subsidiaries have collectively won a State Grid procurement project worth approximately 2.98 billion yuan [22] - Changan Automobile's joint venture has submitted a listing application to the Hong Kong Stock Exchange [23] Group 9 - Yinlun Co., Ltd. plans to invest approximately 133 million yuan to acquire a controlling stake in Shenzhen Deep Blue Electronics [24] - Zhongfu Information intends to increase its wholly-owned subsidiary's capital by 380 million yuan [24] - Financial Street's major shareholder has reduced its stake by 0.25% [25] Group 10 - Audiwei has formally submitted an application for H-share listing [26] - Zhongcai Technology's private placement application has been accepted by the Shenzhen Stock Exchange [27] - Haowei Group's subsidiary plans to invest 200 million yuan in a private equity fund focused on semiconductor investments [28] Group 11 - Jinkai New Energy is planning to transfer 51% of its subsidiary's equity to introduce strategic investors [31] - Huafeng Technology has reduced its fundraising target for a private placement to no more than 972 million yuan [32] - Mindray Medical's chairman plans to increase his stake in the company by 200 million yuan [33] Group 12 - Zhongman Petroleum's shareholders plan to reduce their holdings by up to 3% [35] - Innovation New Materials' shareholder intends to reduce their stake by up to 1% [37] - Guangdong Construction has signed a framework agreement to establish a quality testing base in Linzhi Economic Development Zone [39]

Group 1 - The company Demais (SZ 301007) announced on November 28 that its fourth board meeting will be held in a combined format of on-site and communication to review the proposal for adjusting the share repurchase plan [1] - For the first half of 2025, the company's revenue composition shows that manufacturing accounts for 99.34% while other businesses account for 0.66% [1] - As of the report, the market capitalization of Demais is 5.5 billion yuan [1]

Group 1 - The company, Demais (301007.SZ), announced an adjustment to the maximum repurchase price of its shares, increasing it from 23.69 yuan per share to 45.00 yuan per share [1]

证券代码：301007 证券简称：德迈仕 公告编号：2025-050 大连德迈仕精密科技股份有限公司 第四届董事会第十次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记 载、误导性陈述或重大遗漏。 一、董事会会议召开情况 1、本次大连德迈仕精密科技股份有限公司（以下简称"公司"）本次会议通知于2025 年11月25日以书面方式等《公司章程》规定的方式送达至各位董事。 公司的上市地位，亦不会导致公司控制权发生变化，不存在损害公司、股东特别是中小股 东利益的情形。 具体内容详见公司在中国证监会指定信息披露网站巨潮资讯网（www.cninfo.com.cn） 披露的《关于调整回购公司股份价格上限的公告》。 2、本次公司董事会于2025年11月28日上午11:00以现场及通讯结合方式召开，以记名 投票方式表决。 3、本次公司董事会应出席董事9人，其中现场出席董事1人，通讯出席董事8人，没有 董事委托其他董事代为出席或缺席会议。 4、本次公司董事会由董事长潘异先生主持，公司总经理、董事会秘书及证券事务代 表列席了会议。 5、本次公司董事会召开符合《中华人民共和国公司法》（以下简称"《 ...

证券代码：301007 证券简称：德迈仕 公告编号：2025-051 大连德迈仕精密科技股份有限公司 关于调整回购公司股份价格上限的公告 截至本公告日，公司尚未实施本次股份回购。 三、本次调整回购方案的具体情况 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记 载、误导性陈述或重大遗漏。 重要内容提示： 1、本次调整回购股份方案的具体内容：将回购股份价格上限由23.69元/股（含）调 整至45.00元/股（含）。 2、除调整回购股份价格的上限外，回购股份方案的其他内容未发生变化。 3、回购股份价格上限调整的生效日期为2025年12月1日。 大连德迈仕精密科技股份有限公司（以下简称"公司"）于2025年11月28日召开第 四届董事会第十次会议审议通过了《关于调整回购公司股份方案的议案》，同意公司将 回购股份价格上限由23.69元/股（含）调整至45.00元/股（含），除调整回购股份价格的 上限外，回购股份方案的其他内容未发生变化，现将相关情况公告如下： 一、本次回购股份方案调整前的基本情况 公司于2025年4月21日召开第四届董事会第三次会议审议通过了《关于回购公司股 份方案的议案》，同意 ...

Core Viewpoint - Demais announced the establishment of a new investment partnership, indicating a strategic move to enhance its investment capabilities and expand its portfolio [1] Summary by Categories Investment Partnership - Demais' subsidiary, Suzhou Demais Technology Co., Ltd., has partnered with Hangzhou Yingzhqin Private Fund Management Co., Ltd., and other entities to establish the Hangzhou Deying Zhitou Equity Investment Partnership (Limited Partnership) [1] - The total fund size is set at 100,000 million RMB, showcasing a significant commitment to investment [1] Contributions and Ownership Structure - Suzhou Demais contributed 25 million RMB, representing 2.50% of the partnership [1] - Dalian Demais Investment Co., Ltd. contributed 244 million RMB, holding a 24.40% stake [1] - Suzhou Huixin Chuangzhi Investment Co., Ltd. contributed 1 million RMB, accounting for 0.10% [1] - Other partners collectively contributed 730 million RMB, making up 73.00% of the fund [1] Legal Framework - The partnership agreement for the Hangzhou Deying Zhitou Equity Investment Partnership has been signed by Suzhou Demais and all partners involved [1]

证券代码：301007 证券简称：德迈仕 公告编号：2025-049 大连德迈仕精密科技股份有限公司 关于子公司与关联方共同投资基金的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记 载、误导性陈述或重大遗漏。 一、本次投资的概述 大连德迈仕精密科技股份有限公司（以下简称"公司"）之子公司苏州德迈仕技术有 限公司（以下简称"苏州德迈仕"）与杭州盈智勤私募基金管理有限公司（以下简称"杭 州盈智勤"）、公司关联方大连德迈仕投资有限公司（以下简称"德投"）及苏州汇心创 智投资有限公司（以下简称"汇心创智"）和其他有限合伙人共同投资设立杭州德盈智投 股权投资合伙企业（有限合伙）（以下简称"合伙企业"或"基金"）。基金规模为100,000 万元人民币，其中苏州德迈仕作为有限合伙人以自有或自筹资金出资2,500万元人民币， 占合伙企业2.50%的份额；德投作为有限合伙人以自有或自筹资金方式出资24,400万元 人民币，占合伙企业24.40%的份额；汇心创智作为普通合伙人以自有资金方式出资100 万元人民币，占合伙企业0.10%的份额；其他合伙人合计出资73,000万元人民币，占合 伙企业7 ...

Core Viewpoint - Demai Technology (301007) reported that as of November 20, 2025, the number of registered shareholders is approximately 13,200 [1] Summary by Categories - **Company Information** - Demai Technology has approximately 13,200 registered shareholders as of the specified date [1]

Core Viewpoint - Demais (301007.SZ) announced that its subsidiary, Suzhou Demais Technology Co., Ltd., plans to jointly invest in establishing a private equity partnership named Hangzhou Deying Zhito Equity Investment Partnership with several partners, focusing on high-end equipment and new productive forces [1] Group 1: Investment Details - Suzhou Demais intends to contribute up to 25 million RMB, representing a 2.50% stake in the partnership [1] - Dalian Demais Investment Co., Ltd. (the controlling shareholder) plans to invest up to 244 million RMB for a 24.40% stake [1] - Suzhou Huixin Chuangzhi Investment Co., Ltd. will act as a general partner, contributing up to 1 million RMB for a 0.10% stake [1] Group 2: Fund Structure and Status - The partnership is still in the preparatory and fundraising stage, with some limited partners yet to be determined [1] - The partnership has not yet been established, and the partners have not signed the partnership agreement [1] - The investment focus is on high-end equipment and new productive forces, indicating a strategic direction for future growth [1]